321574-29-2Relevant articles and documents
Synthesis and anti-tumor activity evaluation of salinomycin C20-O-alkyl/benzyl oxime derivatives
Duan, Wenfang,Hao, Jie,Hu, Yuhua,Li, Bo,Li, Tianlei,Li, Zhongwen,Lian, Xu,Qin, Tong,Tang, Lei,Wu, Jun,Wu, Song,Zhang, Chi,Zhang, Jihong,Zhang, Wenxuan,Zhao, Xintong
, p. 870 - 876 (2022/02/03)
Seventeen C20-O-alkyl/benzyl oxime derivatives were synthesized by a concise and effective method. Most of these derivatives showed tens to several hundred nanomolar IC50 values against HT-29 colorectal, HGC-27 gastric and MDA-MB-231 breast cancer cells, whose antiproliferative activity is 15-240 fold better than that of salinomycin. The C20-oxime etherified derivatives can coordinate potassium ions, and further adjust the cytosolic Ca2+ concentrations in HT-29 cells. The significant improvement of the potency should be attributed to the better ion binding and transport ability of the modified derivatives. In addition, the C20-O-alkyl/benzyl oxime derivatives showed much better selectivity indexes (SI) than salinomycin, indicating that they present lower neurotoxic risk.
Design, synthesis and evaluation of oxime-functionalized nitrofuranylamides as novel antitubercular agents
Fan, Yi-Lei,Wu, Jian-Bing,Ke, Xing,Huang, Zhong-Ping
supporting information, p. 3064 - 3066 (2018/08/21)
A series of oxime-functionalized nitrofuranylamides were designed, synthesized and evaluated for their in vitro anti-mycobacterial activities against MTB H37Rv and drug-resistant clinical isolates. Among them, two compounds 7a and 7b exhibited excellent activity against the three tested strains. Both of them were comparable to the first-line anti-TB agents INH and RIF against MTB H37Rv, and were far more potent than INH and RIF against MDR-TB 16833 and 16995 strains. Thus, both of them could act as leads for further optimization.
OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA
-
Paragraph 0214; 0215, (2016/04/19)
Compounds of the general formula (I), including their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds and the intermediates involved in their preparation.